News of Daprodustat

The authoritative journal Kidney International has released the Quality of Life Measurement Study on HIF-PHI daprodustat (ASCEND-NHQ). Daprodustat monotherapy can significantly increase hemoglobin (Hb) levels in non dialysis CKD patients and improve fatigue symptoms in patients with mild to moderate anemia.

Kyowa Kirin launched the new anemia drug daprodustat tablets in the Japanese market in June 2020, further demonstrating the importance and application prospects of daprodustat in the international pharmaceutical market.

Daprodustat

Indications： daprodustat is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.

Scan code
Whatsapp

Medicine-related columns

Recommended Articles

There is no data under this category！

Lucius Pharmaceuticals

Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More